Scholarlink

<p>This study evaluates mobility in patients with multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and Parkinson’s disease (PD) by integrating clinical assessments, instrumented gait analysis (IGA) in the hospital, and 1 week of physical activity monitoring (PAM) at home, using wearable sensors. Clinical scores provide a broad measure of disease severity but lack precision in quantifying gait impairments. IGA offers objective gait metrics under standardized conditions, identifying deficits in stride dynamics and postural control. However, these controlled assessments do not reflect real-world mobility. PAM addresses this gap by continuously tracking movement patterns and physical activity during daily-life, offering insights into how patients walk beyond clinical settings. The combination of IGA and PAM provides a more comprehensive understanding of mobility limitations, particularly in MSA and PSP, where gait and balance impairments differ from PD. This dual approach enhances patient assessment, supports personalized disease management, and improves clinical decision-making. Trial registration: ClinicalTrials.gov, NCT04608604, date of registration: 19/10/2020, first patient enrollment: 01/02/2021.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Moving beyond the hospital: in-depth characterization of daily-life mobility in patients with atypical Parkinsonian disorders

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月12日

查看全文
  • Victoria Sidoroff,
  • Hamid Moradi,
  • Gaëlle Prigent,
  • Frank Jagusch,
  • Isabelle Teckenburg,
  • Marzieh Asalian,
  • Nina Hergenroeder-Lenzner,
  • Marijus Giraitis,
  • Eva Tabea Schoenfeldt-Reichmann,
  • Jean-Pierre Ndayisaba,
  • Georg Goebel,
  • Klaus Seppi,
  • Anisoara Ionescu,
  • Florian Krismer,
  • David Benninger,
  • Juergen Winkler,
  • Bjoern M. Eskofier,
  • Jochen Klucken,
  • Kamiar Aminian,
  • Gregor Wenning,
  • Stefano Sapienza,
  • Heiko Gassner,
  • Cecilia Raccagni

摘要

This study evaluates mobility in patients with multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and Parkinson’s disease (PD) by integrating clinical assessments, instrumented gait analysis (IGA) in the hospital, and 1 week of physical activity monitoring (PAM) at home, using wearable sensors. Clinical scores provide a broad measure of disease severity but lack precision in quantifying gait impairments. IGA offers objective gait metrics under standardized conditions, identifying deficits in stride dynamics and postural control. However, these controlled assessments do not reflect real-world mobility. PAM addresses this gap by continuously tracking movement patterns and physical activity during daily-life, offering insights into how patients walk beyond clinical settings. The combination of IGA and PAM provides a more comprehensive understanding of mobility limitations, particularly in MSA and PSP, where gait and balance impairments differ from PD. This dual approach enhances patient assessment, supports personalized disease management, and improves clinical decision-making. Trial registration: ClinicalTrials.gov, NCT04608604, date of registration: 19/10/2020, first patient enrollment: 01/02/2021.